The invention relates to endogenous ligands of a previously orphan G protein coupled receptor GPR17. GPR17 which is preferentially expressed in organs that typically undergo ischemic damage (brain, heart and kidney) is dually activated by two chemically distinct unrelated classes of endogenous inflammatory molecules: nucleotides and cysteinyl-leucotrienes. The invention also shows a role for GPR17 in brain ischemic damage. In vivo experiments have already shown the beneficial cytoprotective effect associated to GPR17 inhibition
Gpr17 modulators, method of screening and uses thereof / P. Ciana, M.L. Trincavelli, C. Verderio, G.E. Rovati, M.P. Abbracchio, C. Martini.
Gpr17 modulators, method of screening and uses thereof
P. CianaPrimo
;G.E. Rovati;M.P. AbbracchioPenultimo
;
2006
Abstract
The invention relates to endogenous ligands of a previously orphan G protein coupled receptor GPR17. GPR17 which is preferentially expressed in organs that typically undergo ischemic damage (brain, heart and kidney) is dually activated by two chemically distinct unrelated classes of endogenous inflammatory molecules: nucleotides and cysteinyl-leucotrienes. The invention also shows a role for GPR17 in brain ischemic damage. In vivo experiments have already shown the beneficial cytoprotective effect associated to GPR17 inhibition
| File | Dimensione | Formato | |
|---|---|---|---|
|
ciana et al embo journal 2006.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
532.81 kB
Formato
Adobe PDF
|
532.81 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
